Harbour Capital Advisors LLC Acquires Shares of 16,675 Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Harbour Capital Advisors LLC acquired a new stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 16,675 shares of the company’s stock, valued at approximately $259,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after buying an additional 1,509 shares in the last quarter. Quarry LP raised its position in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after purchasing an additional 3,108 shares during the period. EntryPoint Capital LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $109,000. Sandia Investment Management LP acquired a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth approximately $90,000. Finally, Fred Alger Management LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth approximately $99,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CNTA. Guggenheim increased their price target on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Jefferies Financial Group increased their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Oppenheimer reiterated an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. B. Riley began coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. Finally, Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $25.17.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $16.05 on Friday. Centessa Pharmaceuticals plc has a 12-month low of $5.58 and a 12-month high of $17.59. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -11.30 and a beta of 1.46. The business has a 50 day simple moving average of $14.69 and a 200 day simple moving average of $11.35. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). On average, equities research analysts anticipate that Centessa Pharmaceuticals plc will post -1.68 EPS for the current year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 4,169 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total transaction of $51,362.08. Following the completion of the transaction, the chief executive officer now directly owns 827,755 shares of the company’s stock, valued at approximately $10,197,941.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total transaction of $51,362.08. Following the completion of the sale, the chief executive officer now directly owns 827,755 shares of the company’s stock, valued at $10,197,941.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gregory M. Weinhoff sold 16,619 shares of the firm’s stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $15.69, for a total value of $260,752.11. Following the sale, the insider now directly owns 206,750 shares of the company’s stock, valued at approximately $3,243,907.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 288,492 shares of company stock valued at $4,641,902. 11.59% of the stock is owned by corporate insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.